Results 101 to 110 of about 6,421 (186)

Eligibility for Nirmatrelvir/Ritonavir Among Adults With an Acute Care COVID-19 Encounter: A Retrospective Cohort Study From Alberta, Canada. [PDF]

Pharmacoepidemiol Drug Saf
Aponte-Hao S, Vu K, Randall JR, Martins KJB, Nguyen PU, Saxinger L, Leal J, Rennert-May E, Rafferty E, Williamson T, Klarenbach SW.   +10 more
europepmc   +1 more source

Evolving role of novel COVID-19 Medicine Delivery Units [PDF]

, 2022
Goodman, Anna, Packham, Alice, Spence, Niamh   +2 more
core  

Underutilization of nirmatrelvir/ritonavir in eligible COVID-19 patients. [PDF]

Eur J Clin Microbiol Infect Dis
de Arpe CF, Homen R, Valls-Carbó A, Barrado J, Olmos-Mata C, Pérez-Somarriba J, Muñoz-Gomez A, Núñez-Orantos MJ, Cabello-Clotet N, Estrada V.   +9 more
europepmc   +1 more source

Effectiveness of Nirmatrelvir/Ritonavir in Unvaccinated COVID-19 Patients Treated in the Emergency Department: A Retrospective Propensity-Matched Cohort Analysis. [PDF]

Ther Adv Pulm Crit Care Med
Jehle DVK, Sunesra R, Williams SM, Bilby NJ, Paul KK, Hill K.   +5 more
europepmc   +1 more source

Greater benefits of immediate nirmatrelvir-ritonavir initiation for post-COVID outcomes: a population-based retrospective cohort study. [PDF]

Nat Commun
Chong KC, Wei Y, Wong CKH, Xiong X, Wang H, Hung CT, Li C, Yam CHK, Chow TY, Guo Z, Li K, Yang A, Mok CKP, Hui DSC, Zhao S, Yeoh EK, Lin G.   +16 more
europepmc   +1 more source

Analysis of California Senate Bill 1473: COVID-19 Therapeutics [PDF]

, 2022
California Health Benefits Review Program
core  

Evaluation of a Protocol Managing the Cyclosporine and Nirmatrelvir/Ritonavir Interaction in Kidney Transplant Recipients. [PDF]

Kidney360
Agtarap K, Giguère P, Deschênes MJ, DeVreese L, McDougall J, Hoar S, Hiremath S.   +6 more
europepmc   +1 more source

Randomized trial of nirmatrelvir/ritonavir versus placebo for adults with acute COVID-19 to prevent long COVID: PanoramicNOR Trial. [PDF]

Trials
Blomberg B, Myklebust NN, Oppegaard O, Tøndel C, Cox RJ, Iversen A, Lehmann ME, Sandvig A, Dahl TB, Valderhaug VD, Szodoray P, Wilhelmsen M, Kirsebom BE, Glambek M, Kaarbøe O, Aukrust P, Lie RT, Langeland N.   +17 more
europepmc   +1 more source

Real-world untreated risk of hospitalization and death in a nirmatrelvir/ritonavir treatment-eligible population with mild-to-moderate COVID-19 in the United States: a systematic literature review. [PDF]

BMC Infect Dis
Migliaccio-Walle K, Mugwagwa T, Cha-Silva AS, Gong CL, Campbell D, Quercia R, Bergroth T, Veenstra DL, Moran MM, Dzingina M.   +9 more
europepmc   +1 more source

Effectiveness of nirmatrelvir/ritonavir and molnupiravir in reducing the risk of short-term and long-term cardiovascular complications of COVID-19: a target trial emulation study. [PDF]

Nat Commun
Guo Z, Wei Y, Lin G, Jia KM, Boyer C, Wang H, Li C, Hung CT, Yam CHK, Chow TY, Zhao S, Li K, Yang A, Mok CKP, Hui DS, Yeoh EK, Chong KC.   +16 more
europepmc   +1 more source